Innovative Diagnostic Portfolio SQI Diagnostics offers a range of advanced, proprietary rapid diagnostic tests targeting critical healthcare areas such as organ transplant monitoring, autoimmune diseases, and COVID-19, positioning it as a versatile partner for healthcare providers seeking cutting-edge solutions.

Recent Market Expansions The company launched the FirstLook Lung test to improve early detection of lung cancer, indicating ongoing development and expansion into critical diagnostic markets with high demand for non-invasive screening tools.

Strategic Funding Support With recent investments totaling over 3 million Canadian dollars from FedDev Ontario and additional debt financing, SQI Diagnostics is well-funded to scale manufacturing efforts and accelerate product commercialization, offering opportunities for sales of new diagnostic technologies.

Regulatory Milestones Receiving Health Canada Interim Order authorization for the RALI-Dx IL-6 Severity Triage Test enhances credibility and market readiness, enabling sales into Canada's healthcare system and expanding potential for international expansion.

Growing Industry Presence Operating in a competitive biotech landscape with other notable firms like Regulus Therapeutics and Cytovance Biologics, SQI Diagnostics is positioned for growth through innovative solutions, strategic partnerships, and expanding product pipelines, creating multiple opportunities for targeted outreach.